AdvanDx Gets FDA OK for Faster Staphylococcus Dx | GenomeWeb

NEW YORK (GenomeWeb News) – Molecular diagnostics firm AdvanDx said today that it has received US Food and Drug Administration clearance for faster versions of its Staphylococcus aureus and S. aureus/coagulase-negative Staphylococci diagnostic tests.

The new versions of the tests, which use peptide nucleic acid fluorescence in situ hybridization (PNA FISH), take 90 minutes to provide results instead of 2.5 hours for conventional tests because PNA probe hybridization is reduced from 90 minutes to 30 minutes, AdvanDx said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.